Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

61. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. Full Text available with Trip Pro

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. Treatment of patients younger than 18 years of age with multiple sclerosis has not been adequately examined in randomized trials. We compared fingolimod with interferon beta-1a in this population.In this phase 3 trial, we randomly assigned patients 10 to 17 years of age with relapsing multiple sclerosis in a 1:1 ratio to receive oral fingolimod at a dose of 0.5 mg per day (0.25 mg per day for patients with a body (...) ; relative difference, 82%; P<0.001). The key secondary end point of the annualized rate of new or newly enlarged lesions on T2-weighted magnetic resonance imaging (MRI) was 4.39 with fingolimod and 9.27 with interferon beta-1a (absolute difference, 4.88 lesions; relative difference, 53%; P<0.001). Adverse events, excluding relapses of multiple sclerosis, occurred in 88.8% of patients who received fingolimod and 95.3% of those who received interferon beta-1a. Serious adverse events occurred in 18

2018 NEJM Controlled trial quality: predicted high

62. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. Full Text available with Trip Pro

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 and can cross the blood-brain barrier, with potential salutary effects in progressive multiple sclerosis.We enrolled patients with primary or secondary progressive multiple sclerosis in a phase 2 randomized trial of oral ibudilast (≤100 mg (...) less brain-tissue loss with ibudilast over a period of 96 weeks. Adverse events with ibudilast included gastrointestinal symptoms, headache, and depression.In a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache, and depression. (Funded by the National Institute of Neurological Disorders and Stroke and others; NN102/SPRINT

2018 NEJM Controlled trial quality: predicted high

63. Tumefactive multiple sclerosis masquerade as a central nervous system tumor: a case report Full Text available with Trip Pro

Tumefactive multiple sclerosis masquerade as a central nervous system tumor: a case report Tumefactive multiple sclerosis is a demyelinating disorder that appears tumor-like on MRI. To most physicians, diagnosing tumefactive MS by applying clinical, radiological, or laboratory examination like Cerebrospinal fluid (CSF) analysis, can be challenging and ultimately biopsy is necessary to confirm the diagnosis.This paper reports a case of a 37-year-old woman who presented with progressive headache

2018 Electronic physician

64. Multiple sclerosis

Multiple sclerosis Top results for multiple sclerosis - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (...) (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for multiple sclerosis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many

2018 Trip Latest and Greatest

65. Moderators of Treatment Outcomes After Telehealth Self-Management and Education in Adults With Multiple Sclerosis: A Secondary Analysis of a Randomized Controlled Trial (Abstract)

Moderators of Treatment Outcomes After Telehealth Self-Management and Education in Adults With Multiple Sclerosis: A Secondary Analysis of a Randomized Controlled Trial To examine moderators of treatment effects in a randomized controlled trial comparing a telehealth self-management intervention with a telehealth multiple sclerosis (MS) education intervention for fatigue, pain, and mood in adults with MS.Secondary analysis of a single-blind randomized controlled trial.Community.Adults with MS

2018 EvidenceUpdates

66. Pharmacological treatment for memory disorder in multiple sclerosis

Pharmacological treatment for memory disorder in multiple sclerosis Pharmacological treatment for memory disorder in multiple sclerosis - He, D - 2013 | Cochrane Library Cookies Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in . Trusted evidence. Informed decisions. Better health (...) Collections Pharmacological treatment for memory disorder in multiple sclerosis Cochrane Systematic Review - Intervention Version published: 17 December 2013 New search Collapse all Expand all Abstract available in Background This is an update of the Cochrane review "Pharmacologic treatment for memory disorder in multiple sclerosis" (first published in The Cochrane Library 2011, Issue 10). Multiple sclerosis (MS) is a chronic immune‐mediated, inflammatory, demyelinating, neurodegenerative disorder

2018 European Academy of Neurology

67. Ocrelizumab for treating relapsing?remitting multiple sclerosis

Ocrelizumab for treating relapsing?remitting multiple sclerosis Ocrelizumab for treating Ocrelizumab for treating relapsing–remitting multiple sclerosis relapsing–remitting multiple sclerosis T echnology appraisal guidance Published: 25 July 2018 nice.org.uk/guidance/ta533 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 22Contents Contents 1 Recommendations 4 2 Information about

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

68. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study Full Text available with Trip Pro

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS).Patients (n = 232) were randomized to ofatumumab 3, 30, or 60 mg every 12 weeks, ofatumumab 60 mg every 4 weeks, or placebo for a 24-week treatment period, with a primary endpoint of cumulative number of new

2018 EvidenceUpdates Controlled trial quality: uncertain

69. Multiple sclerosis: a drug that should never have been authorised

Multiple sclerosis: a drug that should never have been authorised Prescrire IN ENGLISH - Spotlight ''Multiple sclerosis: a drug that should never have been authorised'', 1 July 2018 {1} {1} {1} | | > > > Multiple sclerosis: a drug that should never have been authorised Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Multiple sclerosis: a drug (...) that should never have been authorised In March 2018, after several deaths, daclizumab (Zinbryta°) was withdrawn from the market. The European Medicines Agency should never have authorised this drug. In patients with multiple sclerosis, interferon beta is the first-choice treatment, for want of a better option. Despite the severity of multiple sclerosis in some patients, there is no justification for exposing them to drugs such as alemtuzumab, natalizumab or teriflunomide, whose harm-benefit balance

2018 Prescrire

70. Beta interferons and glatiramer acetate for treating multiple sclerosis

Beta interferons and glatiramer acetate for treating multiple sclerosis Beta interferons and glatir Beta interferons and glatiramer acetate amer acetate for treating multiple sclerosis for treating multiple sclerosis T echnology appraisal guidance Published: 27 June 2018 nice.org.uk/guidance/ta527 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 29Contents Contents 1

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

71. Investigating the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis: a randomized controlled trial (Abstract)

Investigating the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis: a randomized controlled trial To evaluate the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis.It was a three-arm parallel randomized clinical trial study.Outpatient clinic.Patients with multiple sclerosis.Participants in the intervention groups completed an eight-week program consisting (...) obtained for the sexual function of mindfulness group were 19.5 ± 6.4, 26.9 ± 4.8, and 25.6 ± 4.5, respectively. Moreover, mean scores obtained for pelvic floor muscle exercise along with mindfulness were 19.6 ± 5.9, 25.3 ± 5.4, and 25 ± 4.8, respectively. There was no significant difference in their effects on sexual function ( P > 0.05).Mindfulness and pelvic floor muscle exercise do not have any significant impact upon sexual dysfunction of people with multiple sclerosis.

2018 EvidenceUpdates

72. Multiple sclerosis

Multiple sclerosis Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading

2018 Trip Evidence Maps

73. Teriflunomide (Aubagio) - relapsing remitting multiple sclerosis (RRMS)

Teriflunomide (Aubagio) - relapsing remitting multiple sclerosis (RRMS) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved

2018 Health Canada - Drug and Health Product Register

74. Practice Guideline Recommendations Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis

Practice Guideline Recommendations Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis AAN Summary of Practice Guideline for Clinicians Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis AAN.com ©2018 American Academy of Neurology This is a summary of the American Academy of Neurology (AAN) publication, “Practice guideline recommendations: Disease-modifying therapies for adults with multiple sclerosis,” which was published in Neurology ® (...) online on April 23, 2018, and appears in the April 24, 2018, print issue. Please refer to the full guideline at AAN.com/guidelines for more information, including definitions of the classifications of evidence and recommendations. Starting Disease-modifying Therapy (DMT) Recommendations Starting: Recommendation 1 Rationale Receiving the diagnosis of multiple sclerosis (MS) is a stressful life event. 4,5 People receiving major diagnoses may not recall much of the information given to them at the time

2018 American Academy of Neurology

75. Comprehensive Systematic Review Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis

Comprehensive Systematic Review Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis 1 Practice guideline: Disease-modifying therapies for adults with multiple sclerosis Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Alexander Rae-Grant, MD 1 ; Gregory S. Day, MD, MSc 2 ; Ruth Ann Marrie, MD, PhD 3 ; Alejandro Rabinstein, MD 4 ; Bruce A.C. Cree, MD, PhD, MAS 5 ; Gary S. Gronseth, MD 6 ; Michael Haboubi (...) of Multiple Sclerosis Centers, Hackensack, NJ 9. Department of Neuroscience, St. Luke’s University Health Network, Bethlehem, PA 10. Department of Neurology, School of Medicine, University of Virginia, Charlottesville 11. Consortium of Multiple Sclerosis Centers, Hackensack, NJ, and Department of Neurology, School of Medicine, Wayne State University, Detroit, MI 12. Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles 13. Neurology Department, Southern

2018 American Academy of Neurology

76. Preapproval and postapproval evidence on drugs for multiple sclerosis (Abstract)

Preapproval and postapproval evidence on drugs for multiple sclerosis To review the evidence supporting the European Union marketing authorization of drugs for multiple sclerosis (MS) and assess how far postmarketing research addresses information gaps at the time of approval.Through its database, we identified drugs approved by the European Medicines Agency and gathered data on pivotal trials from the European Public Assessment Reports and corresponding publications. We searched Medline

2018 EvidenceUpdates

77. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Full Text available with Trip Pro

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology To develop recommendations for disease-modifying therapy (DMT) for multiple sclerosis (MS).A multidisciplinary panel developed DMT recommendations, integrating findings from a systematic review; followed an Institute of Medicine-compliant process to ensure transparency

2018 EvidenceUpdates

78. Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis Full Text available with Trip Pro

Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis Fatigue is a major disabling symptom in many chronic diseases including multiple sclerosis (MS), but treatment options are limited.Here, we tested the effectiveness of a self-guided , interactive, online fatigue management programme (ELEVIDA) based on principles of cognitive behavioural therapy (CBT) and related psychotherapeutic approaches (eg, mindfulness) for reducing fatigue in MS.Patients with MS

2018 EvidenceUpdates

79. The Use of Digital and Remote Communication Technologies as a Tool for Multiple Sclerosis Management: Narrative Review Full Text available with Trip Pro

The Use of Digital and Remote Communication Technologies as a Tool for Multiple Sclerosis Management: Narrative Review Despite recent advances in multiple sclerosis (MS) care, many patients only infrequently access health care services, or are unable to access them easily, for reasons such as mobility restrictions, travel costs, consultation and treatment time constraints, and a lack of locally available MS expert services. Advances in mobile communications have led to the introduction (...) of screening and assessment, disease monitoring and self-management, treatment and rehabilitation, and advice and education. We review each solution, focusing on any clinical evidence supporting their use from prospective trials (including ASSESS MS, Deprexis, MSdialog, and the Multiple Sclerosis Performance Test) and consider the opportunities, barriers to adoption, and potential pitfalls of eHealth technologies in routine health care.©Martin Marziniak, Giampaolo Brichetto, Peter Feys, Uta Meyding-Lamadé

2018 JMIR rehabilitation and assistive technologies

80. Chronic Cerebro-Spinal Venous Insufficiency in Multiple Sclerosis: Is It the End? Full Text available with Trip Pro

Chronic Cerebro-Spinal Venous Insufficiency in Multiple Sclerosis: Is It the End? 29629362 2018 11 14 2288-7970 34 1 2018 Mar Vascular specialist international Vasc Specialist Int Chronic Cerebro-Spinal Venous Insufficiency in Multiple Sclerosis: Is It the End? 16-18 10.5758/vsi.2018.34.1.16 Rasman Alessandro A Department of Political and Social Sciences, University of Trieste, Trieste, Italy. eng Journal Article 2018 03 31 Korea (South) Vasc Specialist Int 101633116 2288-7970 Conflict

2018 Vascular specialist international